Alkermes (ALKS)
(Delayed Data from NSDQ)
$24.19 USD
+0.54 (2.28%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $24.18 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
ALKS 24.19 +0.54(2.28%)
Will ALKS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for ALKS
Alkermes (ALKS) Gets a Buy from Jefferies
Alkermes orexin 2 receptor story ignored by investors, says Jefferies
Buy Rating on Alkermes Based on Promising ALKS-2680 Efficacy in Narcolepsy Type 1 Treatment
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alkermes (ALKS), Eledon Pharmaceuticals (ELDN) and Legend Biotech (LEGN)
Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024